Evidence map›Paper›PMID 42532975›Full record

ArticleInternational journal of cancer2026

DNA Methylation and Transcriptomic Profiles of Wilms Tumour Reveal New Deregulated Genes and Epigenetic Processes Relevant for Tumour Stratification and Management.

Abu Saadat, Francesco Cecere, Federica Rossetti, Laura Pignata, Emilia D'Angelo, Carlo Giaccari, Gaetano Verde, Paola Quarello, Franca Fagioli, Josep Roma and 5 more

Abstract read
In one paragraph

Article in International journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Abu SaadatDepartment of Environmental Biological and Pharmaceutical Sciences and Technologies (DiSTABiF), University of Campania "Luigi Vanvitelli", Caserta, Italy.ORCID https://orcid.org/0000-0001-9636-2513
Francesco CecereDepartment of Environmental Biological and Pharmaceutical Sciences and Technologies (DiSTABiF), University of Campania "Luigi Vanvitelli", Caserta, Italy.
Federica RossettiDepartment of Environmental Biological and Pharmaceutical Sciences and Technologies (DiSTABiF), University of Campania "Luigi Vanvitelli", Caserta, Italy.
Laura PignataDepartment of Environmental Biological and Pharmaceutical Sciences and Technologies (DiSTABiF), University of Campania "Luigi Vanvitelli", Caserta, Italy.
Emilia D'AngeloDepartment of Environmental Biological and Pharmaceutical Sciences and Technologies (DiSTABiF), University of Campania "Luigi Vanvitelli", Caserta, Italy.
Carlo GiaccariDepartment of Environmental Biological and Pharmaceutical Sciences and Technologies (DiSTABiF), University of Campania "Luigi Vanvitelli", Caserta, Italy.
Gaetano VerdeDepartment of Environmental Biological and Pharmaceutical Sciences and Technologies (DiSTABiF), University of Campania "Luigi Vanvitelli", Caserta, Italy.
Paola QuarelloPediatric Onco-Haematology Division, Regina Margherita Children's Hospital, Turin, Italy.ORCID https://orcid.org/0000-0002-1940-7375
Franca FagioliPediatric Onco-Haematology Division, Regina Margherita Children's Hospital, Turin, Italy.
Josep RomaChildhood Cancer and Blood Disorders, Vall d'Hebron Research Institute (VHIR), Barcelona, Spain.
Manel EstellerCancer Epigenetics Group, Josep Carreras Leukaemia Research Institute (IJC), Badalona, Barcelona, Catalonia, Spain.
Enrique de ÁlavaInstitute of Biomedicine of Sevilla (IBiS), Virgen del Rocio University Hospital/CSIC/University of Sevilla/CIBERONC, Seville, Spain.
Flavia CerratoDepartment of Environmental Biological and Pharmaceutical Sciences and Technologies (DiSTABiF), University of Campania "Luigi Vanvitelli", Caserta, Italy.
Andrea RiccioDepartment of Environmental Biological and Pharmaceutical Sciences and Technologies (DiSTABiF), University of Campania "Luigi Vanvitelli", Caserta, Italy.ORCID https://orcid.org/0000-0001-7990-3576
Angela SparagoDepartment of Environmental Biological and Pharmaceutical Sciences and Technologies (DiSTABiF), University of Campania "Luigi Vanvitelli", Caserta, Italy.ORCID https://orcid.org/0000-0003-4352-945X

Funding

Accordo per la Coesione della Regione Campania (Project MARADONA)Associazione Italiana per la Ricerca sul Cancro IG 2020 ID 24405Ministero dell'Università e della Ricerca PRIN 2022B2N2BY
6 · The paper itself

Abstract

Wilms Tumour (WT), the most common kidney cancer in children, presents features of altered kidney development and frequently exhibits molecular alterations at the 11p15.5 imprinted locus, affecting the IGF2 and H19 genes, which contribute to tumour growth and predisposition. The epigenetic landscape beyond 11p15.5 suggests diagnostic and prognostic potential, but its link to transcriptomic changes is largely unexplored. We integrated methylomic and transcriptomic datasets of 27 primary tumours and matched non-neoplastic kidneys. DNA methylation profiling identified around 9000 differentially methylated CpG sites distinguishing neoplastic from non-neoplastic tissue and other paediatric cancers, thus representing a novel WT-specific epigenetic signature. We found that cases with Imprinting Centre 1 (IC1) gain of methylation exhibited the most extensive epigenetic alterations; cases with 11p15.5 loss of heterozygosity showed intermediate changes, whereas regressive tumours with largely normal 11p15.5 status were less affected. Three methylation clusters corresponding to transcriptomic subtypes were identified, characterised by distinct tumour microenvironment and chemosensitivity predictions: a regressive-enriched, immune-infiltrated group predicted to respond to paclitaxel, a proliferative group sensitive to doxorubicin, and a stromal-like intermediate group. Combined analysis of methylation and expression data revealed more than 900 genes under epigenetic control, which contributed to defining the WT subtypes. Analysis of the IGF2/H19 locus uncovered multiple regulatory mechanisms underlying IGF2 activation, including imprinting defects at IC1, methylation changes at DMR0, differential promoter usage and transcriptional modulation by PLAG1 and BAHD1. These findings define the epigenetic alterations underlying WT heterogeneity and support improved molecular stratification and therapeutic approaches.

Indexed as

DNA MethylationEpigenesis, GeneticKidney NeoplasmsTranscriptomeWilms TumorCpG IslandsFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticGenomic ImprintingHumansInsulin-Like Growth Factor IIIGF2 protein, humanInsulin-Like Growth Factor IIDNA methylation profileepigenetic signatureIGF2transcriptomic profileWilms tumour

Identifiers

PMID42532975
PMCPMC13637058

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.